Pfizer outlines 2025 R&D milestones and oncology growth opportunities
Bourla outlined 2025 priorities, which include improving R&D productivity, achieving margin expansion, and maintaining commercial excellence. He highlighted expectations for nine Phase 3 readouts, 13 ...
Pfizer Earnings: After Solid Results, Reaffirmed 2025 Guidance
Pfizer’s PFE 2024 revenue reached $63.6 billion, near the high end of its $61 billion-$64 billion guidance range. Management ...
Pfizer Q4 Earnings: Solid Results, But Guidance And Patent Concerns Drive The Stock Down
Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...
Pfizer Shares Are Falling Today: What's Going On?
Pfizer Inc. (NYSE: PFE) shares are trading lower Tuesday after the Senate Finance Committee voted to advance Robert F. Kennedy Jr.'s nomination for Secretary of Health and Human Services.
Vaccine, Packaged Food Stocks Fall as Kennedy Moves Closer to Health Secretary Job
Kennedy, who has faced opposition from health groups and Democrats, has long sown doubts about the safety and efficacy of ...
Pfizer shows profit growth from cost cuts and steadier COVID sales
U.S. drugmaker Pfizer beat Wall Street estimates for fourth-quarter profit on Tuesday, helped by cost-cutting efforts and ...
Pfizer Shares Rise on Better-Than-Expected 4Q
Investors have been cool to Pfizer, with shares down some 50% since record highs in 2021. Pfizer Chief Executive Albert Bourla has been looking to turn around the company's performance, taking steps ...